Clinically, we are not aware of any major side effects associated with this peptide
It was found through preliminary research that treatment with AOD9604 over the course of 14 days in obese mice led to decreased body weight and body fat and was shown to increase the activity of the beta(3)-adrenergic receptors in the fat cells to the same level as those in lean mice
Injection-Related Risks : Injectable BPC-157 carries risks linked to nonsterile preparation, dosing errors, local infection, irritation, and improper administration
It is most often chosen by post-surgical patients (rotator cuff, ACL, meniscus, fracture or soft tissue surgery), serious athletes managing accumulated wear-and-tear, fighters and combat athletes between camps, runners with chronic Achilles, plantar fascia or knee issues, patients with significant gut inflammation alongside musculoskeletal issues, and high-performers who want comprehensive systemic recovery support